Building a world leading RNA epigenetics company in Cambridge, UK

Opportunity for Cell Biologists

STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. Storm has established a pipeline of novel projects, and is looking to take projects to the clinic.

Following the success of our recent series A extension financing, we are looking to recruit enthusiastic scientists to work in our cell biology team on target validation and/or translational oncology studies to support our small molecule drug discovery programs. The successful candidates will establish innovative cellular assays and use them to explore the utility of inhibitors of RNA modifying enzymes, understand mechanism of action and identify the most sensitive patient populations and develop biomarker assays to define them. In addition, he/she will use genome-editing platforms to identify and validate new drug targets to support our early project pipeline. Positions are available at the scientist or senior scientist level depending on experience and qualifications.

Storm Therapeutics offers an industry competitive salary and benefits package.

STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group and Seroba Life Sciences who share the founders' ambitions to build a world-leading company in the field. To date, STORM Therapeutics has raised £30million of funding. The company occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge.

Qualifications and skills required

Essential qualifications and skills include:

- Significant cell and molecular biology laboratory experience
- Expertise in working with cellular oncology models and cell-based assays
- Cell-based assay development and screening experience
- Knowledge of cancer biology
- Experience of CRISPR, siRNA or shRNA studies for target validation and mechanism of action studies
- Candidates should be legally entitled to work in the UK.

Desirable additional skills:

- Experience of working in cancer drug discovery, preferably in an industrial environment
- PhD in Biology, Biochemistry or another relevant Biological Science discipline

- Experience of identification and monitoring of pharmacodynamic and patient-selection biomarkers
- Experience of complex cell culture models including 3D cell models / organoids
- Experience in working with RNA and analysing RNA Seq experiments
- Experience in oncology translational research

Competencies and skills:

- Strong oral and written communication skills in English
- Pursuit of the highest standards of scientific excellence
- Excellent organisational skills and a systematic and rigorous approach to work.
- Skilled in hypothesis-driven research/problem solving
- Result orientated and deadline driven
- Ability to work independently and as part a multidisciplinary team
- A positive and flexible approach to often changing situations.
- Passion for drug discovery

Apply to: info@stormtherapeutics.com. Closing date 23rd September 2019

www.stormtherapeutics.com

Harnessing the power of RNA epigenetics



STORM THERAPEUTICS

RNA epigenetics in human disease
17-20 September 2019
Cambridge, UK

Website: www.stormtxconference2019.com